Literature DB >> 21427197

Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.

Vincenzo La Mura1, Juan Carlos Reverter, Alexandra Flores-Arroyo, Sebastián Raffa, Enric Reverter, Susana Seijo, Juan G Abraldes, Jaime Bosch, Juan Carlos García-Pagán.   

Abstract

BACKGROUND AND AIMS: Endothelial dysfunction is a major determinant of the increased hepatic vascular tone of cirrhotic livers. Von Willebrand factor (vWF), P-selectin and 8-iso-PGF2α (isoprostanes), surrogate markers of endothelial dysfunction, are increased in patients with cirrhosis. This study was aimed at exploring in patients with cirrhosis and portal hypertension the relation of these endothelial factors with systemic and hepatic haemodynamics and their possible clinical prognostic value.
METHODS: 42 consecutive patients with cirrhosis and portal hypertension had measurement of the hepatic venous pressure gradient (HVPG), cardiopulmonary pressures and vWF, P-selectin and isoprostane levels in blood samples from hepatic and peripheral veins. Patients were followed up to 2 years, death or liver transplantation and any clinical event were recorded.
RESULTS: vWF, P-selectin and isoprostanes were increased in patients with cirrhosis compared with controls (p<0.001). vWF levels significantly correlated with HVPG, Child-Pugh score and MELD. Cox model analysis disclosed an independent indirect association of peripheral vWF with survival free of portal hypertension-related events and of transplantation. The vWF cut-off value of 216 U/dl (Youden index) disclosed two different populations of patients with cirrhosis with a highly different probability of survival free of portal hypertension-related events and transplantation (87% vs 22%, p=0.001). The prognostic role of vWF persisted after adjusting for parameters of liver dysfunction and for HVPG.
CONCLUSIONS: In patients with cirrhosis and portal hypertension vWF levels correlate with liver function and HVPG and independently predict clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21427197     DOI: 10.1136/gut.2010.235689

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  38 in total

1.  Von Willebrand factor and alkaline phosphatase predict re-transplantation-free survival after the first liver transplantation.

Authors:  Andreas Wannhoff; Conrad Rauber; Kilian Friedrich; Christian Rupp; Wolfgang Stremmel; Karl Heinz Weiss; Peter Schemmer; Daniel N Gotthardt
Journal:  United European Gastroenterol J       Date:  2016-07-08       Impact factor: 4.623

2.  ADAMTS13 deficiency, despite well-compensated liver functions in patients with noncirrhotic portal hypertension.

Authors:  Ashish Goel; P L Alagammai; Sukesh C Nair; Ian Mackie; Banumathi Ramakrishna; Jayaprakash Muliyil; Shyamkumar N Keshava; C E Eapen; Elwyn Elias
Journal:  Indian J Gastroenterol       Date:  2014-04-24

3.  Von Willebrand factor deficiency reduces liver fibrosis in mice.

Authors:  Nikita Joshi; Anna K Kopec; Jessica L Ray; Holly Cline-Fedewa; Dafna J Groeneveld; Ton Lisman; James P Luyendyk
Journal:  Toxicol Appl Pharmacol       Date:  2017-05-17       Impact factor: 4.219

4.  Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failure.

Authors:  K S Prasanna; Ashish Goel; G Jayakumar Amirtharaj; Anup Ramachandran; K A Balasubramanian; Ian Mackie; Uday Zachariah; K G Sajith; Elwyn Elias; C E Eapen
Journal:  Indian J Gastroenterol       Date:  2016-11-08

5.  Significant Association between Serum Levels of Von Willebrand Factor (vWF) Antigen with Stages of Cirrhosis.

Authors:  Vural Taner Yilmaz; Dinc Dincer; Ali Berkant Avci; Ramazan Cetinkaya
Journal:  Eurasian J Med       Date:  2015-02

Review 6.  Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement.

Authors:  Vincenzo La Mura; Antonio Nicolini; Giulia Tosetti; Massimo Primignani
Journal:  World J Hepatol       Date:  2015-04-08

Review 7.  Coagulopathy in liver disease: Lack of an assessment tool.

Authors:  Annabel Blasi
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

Review 8.  New prognostic markers in liver cirrhosis.

Authors:  Vincent Di Martino; Delphine Weil; Jean-Paul Cervoni; Thierry Thevenot
Journal:  World J Hepatol       Date:  2015-05-28

Review 9.  New determinants of prognosis in bacterial infections in cirrhosis.

Authors:  Juan Acevedo; Javier Fernández
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

10.  Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo-coagulable and Hyper-coagulable Features.

Authors:  Alberto Zanetto; Henry M Rinder; Elena Campello; Graziella Saggiorato; Yanhong Deng; Maria Ciarleglio; Francis P Wilson; Marco Senzolo; Sabrina Gavasso; Cristiana Bulato; Paolo Simioni; Guadalupe Garcia-Tsao
Journal:  Hepatology       Date:  2020-10       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.